A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic.
A 6-thioguanine-resistant (TgR) variant of the metastatic mammary tumor 13762 was found to be very immunogenic. This TgR variant was nontumorigenic and nonmetastatic, whereas the parent 13762 cell line is very tumorigenic and metastatic in normal syngeneic animals. The TgR variant was tumorigenic in irradiated animals. The mechanism of the hosts' immune rejection of this TgR variant was investigated. A 51Cr-release cytotoxic cell assay was used to assess lymphocyte cell-mediated cytotoxicity (CMC) of tumor-draining lymph nodes and spleens from animals injected with tumor cells. In a secondary CMC response of splenic T cells from animals injected with TgR cells, there was a much stronger response as compared to animals injected with 13762 cells. This strong cytotoxic T cell response was short-term and correlated to the host rejection of TgR cells. Previously, we selected revertant cell lines (TgRrev, TgRrevM) from the TgR variant line that were more metastatic and tumorigenic. The revertant cell lines induced a lower CMC response than the TgR line, but a higher response compared to the parent 13762 line. The poor CMC response from 13762 tumor-bearing animals was investigated and appeared to be due to a suppressor T cell response.
D000230:Adenocarcinoma / Q000235:genetics / Q000276:immunology*; D000818:Animals; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D004351:Drug Resistance; D005260:Female; D014644:Genetic Variation; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000276:immunology*; D051381:Rats; D011916:Rats, Inbred F344; D013601:T-Lymphocytes / Q000276:immunology; D013866:Thioguanine / Q000633:toxicity*
D013866:Thioguanine